0.01
+0.99%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Alligator Bioscience
Its shares trade on Nasdaq Stockholm under the ticker ATORX.ST. It has been listed since 23 November 2016. In the fiscal year to 31 December 2025, it reported revenue of SEK 514,000 and a net loss of SEK 51.4m. At that date it held total assets of SEK 110.6m and shareholders' equity of SEK 6.9m.
Alligator Bioscience AB is a biotech company, which engages in the development of innovative antibody- based medicines for immunotherapy of cancer. The company is headquartered in Lund, Skane. The company went IPO on 2016-11-23. The firm specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. In the discovery of those drugs, the Company uses its technology platforms ALLIGATOR-GOLD and FIND. ALLIGATOR-GOLD is a library containing human antibodies. FIND (which stands for Fragment Induced Diversity) is an antibody optimization technology. In its pipeline, the Company has thee projects: ADC-1013 (antibody), ATOR-1015 (bispecific immune activating antibody) and ATOR-1016 (bispecific agonistic antibody), which are in research/preclinical stage.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 23 Nov 2016
- Employees
- 43
- Website
- alligatorbioscience.se ↗
Leadership
Pay as last reported
- Mr. Hans-Peter OstlerNon-Executive Chairman of the BoardSEK 525,000
- Dr. Soren BregenholtChief Executive OfficerSEK 5.2m
- Mr. Johan GileusChief Financial Officer
- Dr. Laura von SchantzChief Technology Officer, since 2017
- Dr. Tom MooreChief Medical Officer
- Ms. Karin NordbladhDirector Employee Representative
- Ms. Denise GoodeIndependent DirectorSEK 325,000
- Ms. Eva Sjoekvist SaersIndependent DirectorSEK 350,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 38
- Environment
- 34
- Social
- 37
- Governance
- 44
- Women in the workforce
- 69.23077%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Alligator Bioscience AB develops innovative antibody-based medicines for cancer immunotherapy.
- The company uses ALLIGATOR-GOLD and FIND technology platforms for antibody discovery.
- Alligator Bioscience AB has three pipeline projects in research/preclinical stage.
Weaknesses
- Alligator Bioscience AB has only 43 employees as of 2023.
- The company's IPO was on 23 November 2016.
- Alligator Bioscience AB focuses on early-stage research with no approved drugs.
Opportunities
- Alligator Bioscience AB can expand its pipeline with new antibody projects.
- The biotechnology sector in Sweden offers growth opportunities for Alligator Bioscience AB.
- The company can leverage its technology platforms for partnerships in Health Care.
Threats
- Alligator Bioscience AB faces competition from other biotech companies in Health Care.
- The company's early-stage research may lead to delays in drug development.
- Regulatory challenges in the Health Care industry could impact Alligator Bioscience AB.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.